12 Health Care Stocks Move in Wednesday's After-Market Session: Sharps Technology Leads Gainers with 76.1% Increase
PorAinvest
jueves, 11 de septiembre de 2025, 10:04 am ET1 min de lectura
APM--
The NYSE Health Care Index declined by 0.8%, while the Health Care Select Sector SPDR Fund (XLV) dropped by 1.1% [1]. The iShares Biotechnology ETF (IBB) also decreased by 1.9%. Neurosense Therapeutics (NRSN) saw its shares jump by 18% after positive phase 2 trial results for its Alzheimer's treatment candidate, PrimeC [1]. Merck (MRK) canceled plans for a $1.35 billion research center in London, leading to a 0.8% drop in its shares [1]. Soleno Therapeutics (SLNO) fell by 15% following a report from the US Food and Drug Administration's Adverse Event Reporting System [1]. Actuate Therapeutics (ACTU) shares dropped by 22% after pricing an underwritten public offering [1].
Sharps Technology announced a strategic partnership with Web3 brand Pudgy Penguins to expand its Solana digital asset treasury exposure [2]. The company also entered into a Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co. and Aegis Capital Corp., allowing it to offer and sell shares for up to $236.6 million. Additionally, the company made changes to its leadership team, appointing Paul Danner as executive chairman [2].
Cinctive Capital Management LP reduced its stake in Revolution Medicines, Inc. by 67.4%, holding only 11,343 shares after selling 23,447 shares in the first quarter [3]. Despite this reduction, other investors such as Schonfeld Strategic Advisors LLC and Ameriprise Financial Inc. significantly increased their positions in the company. Analysts maintain a consensus rating of "Buy" for Revolution Medicines, with price targets ranging up to $99.00 [3].
RVMD--
SOL--
STSS--
On Wednesday's after-market session, several health care stocks moved. Sharps Technology's STSS stock increased by 76.1% to $16.28, while Aptorum Group's APM stock rose 26.74% to $2.18. Revolution Medicines' RVMD stock increased by 9.98% to $44.49. Meanwhile, Avidity Biosciences' RNA shares decreased by 22.7% to $35.85. Kewaunee Scientific's KEQU stock fell 16.35% to $45.75.
On Wednesday's after-market session, several health care stocks showed varied movements. Sharps Technology's (STSS) stock surged by 76.1% to $16.28, while Aptorum Group's (APM) stock rose by 26.74% to $2.18. Revolution Medicines' (RVMD) stock increased by 9.98% to $44.49, according to Investing.com [3]. Meanwhile, Avidity Biosciences' RNA shares dropped by 22.7% to $35.85, and Kewaunee Scientific's (KEQU) stock fell by 16.35% to $45.75.The NYSE Health Care Index declined by 0.8%, while the Health Care Select Sector SPDR Fund (XLV) dropped by 1.1% [1]. The iShares Biotechnology ETF (IBB) also decreased by 1.9%. Neurosense Therapeutics (NRSN) saw its shares jump by 18% after positive phase 2 trial results for its Alzheimer's treatment candidate, PrimeC [1]. Merck (MRK) canceled plans for a $1.35 billion research center in London, leading to a 0.8% drop in its shares [1]. Soleno Therapeutics (SLNO) fell by 15% following a report from the US Food and Drug Administration's Adverse Event Reporting System [1]. Actuate Therapeutics (ACTU) shares dropped by 22% after pricing an underwritten public offering [1].
Sharps Technology announced a strategic partnership with Web3 brand Pudgy Penguins to expand its Solana digital asset treasury exposure [2]. The company also entered into a Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co. and Aegis Capital Corp., allowing it to offer and sell shares for up to $236.6 million. Additionally, the company made changes to its leadership team, appointing Paul Danner as executive chairman [2].
Cinctive Capital Management LP reduced its stake in Revolution Medicines, Inc. by 67.4%, holding only 11,343 shares after selling 23,447 shares in the first quarter [3]. Despite this reduction, other investors such as Schonfeld Strategic Advisors LLC and Ameriprise Financial Inc. significantly increased their positions in the company. Analysts maintain a consensus rating of "Buy" for Revolution Medicines, with price targets ranging up to $99.00 [3].
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios